Tag Archive | "Servier"

Shanghai Institute pharma partners with Servier for lucitanib

Tags: , , ,

The Shanghai Institute of Materia Medica pharma partners with Servier, a big pharma company, on China development of lucitanib, a clinical-stage anti-angiogenic cancer drug Read the full story

Pharma partners MacroGenics trigger first milestone payment from Servier

Tags: , , ,

Pharma partners, MacroGenics, announced that the first patient has been dosed in a Phase 1 dose expansion cohort trial of MGA271. Read the full story

Amgen and Servier terminate cardiovascular pharma deals

Tags: , , ,

Amgen and Servier have terminated pharma deals involving the cardiovascular drug Procoralan. Read the full story

Servier: Company Profile

Tags: ,

Servier, a top pharmaceutical company, is reviewed in terms of partnering and licensing interests and activity over recent years Read the full story

Servier, a big pharma company in partnership with NovAliX for drug discovery research program

Tags: , , ,

Servier, a big pharma company has inked a collaboration deal with NovAliX for small molecule drug discovery Read the full story

Servier seals a pharma partners pact with Ethical Oncology Science

Tags: , , ,

Ethical Oncology Science and Servier, a big pharma company have sealed a pharma partners collaboration and license agreement to further develop EOS’ antitumor drug E-3810. Read the full story

Servier & MacroGenics pharma partners to develop three anticancer DART products

Tags: , , , ,

MacroGenics and Servier have entered into an option pharma partners agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets Read the full story

Big pharma partners pact bring Boehringer Ingelheim,XOMA and Servier together

Tags: , , ,

XOMA announced its partner Les Laboratoires Servier and the Company have entered into a pharma partners agreement with Boehringer Ingelheim to transfer XOMA's technology and process for the commercial manufacture of gevokizumab, XOMA's novel interleukin 1-beta (IL-1β) allosteric modulating antibody.

Read the full story

Partnering Agreements with Servier

Tags: , , , , , ,

This report provides all the information you require to better understand Servier and its partnering interests and activities over the past seven years. Read the full story

BioInvent and Servier enter oncology collaboration

Tags: , ,

BioInvent International and Les Laboratoires Servier have entered into an antibody collaboration on an oncology target involved in tumour cell metabolism provided by Servier.  Read the full story